Monthly Archives: June 2012

HIV Prevention And HIV Vaccine

What is in the future for  HIV Vaccine?

Early advances in preventing HIV transmission resulted from educational programs describing how transmission occurs and providing barrier protection for those exposed to genital secretions and new needles or bleach to those exposed to blood by sharing needles. Despite these efforts, new infection in both the developed and developing worlds has continued at high rates.

Historically, the greatest success in preventing viral transmission has resulted from the development of preventative vaccines. Unfortunately, decades of research to develop an HIV vaccine has led to little hope for success. While the vaccine which has been developed demonstrated only limited evidence of protection, research is under way to further explore what can be learned for future vaccine development from this modest success. Continue reading

HIV and Pregnancy

Treatment of Pregnant HIV-Infected Patients:

Pregnant women with HIV infection  should be offered therapy based on the same virologic, immunologic, and clinical parameters as non pregnant women.

The goal of therapy is to provide maximal virologic suppression to optimize the health of the mother and minimize transmission of virus to the fetus. The choice of drugs and the timing of initiating therapy may, however, be influenced by the pregnancy.

Most antiretroviral drugs are safe in pregnant women; to the extent they have been studied. Many of the toxicities caused by antiretroviral agents may contribute to parallel complications of pregnancy, (e.g., the hyperglycemia associated with protease inhibitors may exacerbate pregnancy-associated diabetes). There are specific concerns regarding the use of nucleosides during pregnancy, especially stavudine and didanosine, in view of their association with hepatic steatosis and lactic acidosis in several pregnant women. There is also particular concern about the association of efavirenz with fetal abnormalities in monkeys. Finally, combination ART may be associated with an increased risk for preterm delivery. Antiretroviral regimens must be chosen carefully and monitored.

Transmission of HIV from mother to fetus has been observed at all maternal plasma HIV RNA levels. There seem to be a correlation between the HIV plasma RNA copy number and the risk of transmission. Clinical trials have shown that ART can greatly reduce the likelihood that virus will be transmitted to the fetus or infant. Zidovudine monotherapy and nevirapine monotherapy have been most carefully studied, and both seem to be safe for the mother and fetus and are effective in substantially reducing the rate of maternal-fetal transmission. However, monotherapy is no longer indicated in settings in which combination ART is feasible. Moreover, single-dose nevirapine monotherapy can produce HIV resistance because of the long half-life of nevirapine. It is logical to use combination ART regimens for treating the mother to lower her viral load effectively and produce durable viral suppression.

Current guidelines indicate that combination ART, usually including zidovudine, should be recommended for infected women who meet the standard criteria for treatment or who have HIV RNA levels greater than 1000 copies/mL, regardless of immunologic or clinical status. Women who are in the first trimester of pregnancy may prefer delaying therapy until after 10 to 12 weeks of gestation if they are concerned about the teratogenicity of drugs administered during the early part of their pregnancy. . Prior to antiviral therapy, the risk of HIV transmission from an infected mother to her newborn was approximately 25%-35%. By giving ZDV after the first trimester of pregnancy, then intravenously during the delivery process, and then after delivery to the newborn for six weeks showed a reduction in the risk of transmission to less than 10%. Women who are not receiving zidovudine or nevirapine but who have HIV plasma RNA levels less than 1000 copies/mL seem to have a low risk of transmitting HIV to their offspring. There are no clear guidelines about how best to manage pregnant women whose virus is resistant to zidovudine and nevirapine.

All HIV-infected pregnant women should be managed by an obstetrician with experience in dealing with HIV-infected women. Maximal obstetric precautions to minimize transmission of the HIV virus, such as avoiding scalp monitors and minimizing labor after rupture of the uterine membranes, should be observed. In addition, the potential use of an elective Caesarean section (C-section) should be discussed, particularly in those women without good viral control of their HIV infection where the risk of transmission may be increased. Breastfeeding should be avoided if alternative nutrition for the infant is available since HIV transmission can occur by this route.

Hepatitis B: how is Hepatitis B Transmitted?

How Hepatitis B is transmitted?

The Hepatitis B virus is known as a blood-borne virus because it is transmitted from one person to another via blood or fluids contaminated with blood. Another important route of transmission is from an infected mother to a newborn child, which occurs during or shortly after birth. It is called vertical transmission.

  • Direct contract with blood may occur through the use of dirty needles during illicit drug use, accidental needle pricks experienced by healthcare workers, or contact with blood through other means. Semen, which contain small amounts of blood, and saliva that is contaminated with blood also carry the virus.
  • The virus may be transmitted when these fluids come in contact with broken skin or a mucous membrane (in the mouth, genital organs, or rectum) of an uninfected person. Continue reading

HIV AIDS Services

Lifestyle and Home Remedies:

Although it’s important to receive medical treatment for HIV/AIDS, it’s also essential to take an active role in your own care. The following suggestions may help you stay healthy longer:

  • Eat healthy foods. Emphasize fresh fruits and vegetables, whole grains and lean protein. Healthy foods help keep you strong, give you more energy and support your immune system.
  • Avoid certain foods. Food-borne illnesses can be especially severe in people who are infected with HIV. Avoid unpasteurized dairy products, raw eggs and raw seafood such as oysters, sushi or sashimi. Cook meat until it’s well-done or until there’s no trace of pink color.
  • Get immunizations. These may prevent infections such as pneumonia and the flu. Make sure the vaccines don’t contain live viruses, which can be dangerous for people with weakened immune systems.
  • Take care with companion animals. Some animals may carry parasites that can cause infections in people who are HIV-positive. Cat feces can cause toxoplasmosis, while pet reptiles can carry salmonella. Continue reading

Hepatitis B: Hepatitis B treatment

What is treatment of hepatitis?

Acute infection

Acute infection with hepatitis B usually does not require treatment. In rare cases, however, the infection may cause life-threatening liver failure. Patients with liver failure due to acute hepatitis B should be evaluated for liver transplantation. Small studies suggest that the drug lamivudine (Epivir) may be effective in this setting.

Chronic infection

If a person is chronically infected with hepatitis B and has few signs or symptoms of complications, medications usually are not used. These patients are watched carefully and are advised to go for certain blood tests. One test measures the ‘viral load,’ that is, the amount of viral DNA in the blood. Doctors will recommend treatment if there are signs that the virus is beginning to cause damage or if the viral load is high. Another reason to prescribe medication is if the patient has a positive test for the Hepatitis B e-antigen (HBeAg) in the blood. HBeAg is associated with an increased risk of progression of liver disease and its complications.

In chronic hepatitis B, the goal of treatment is to reduce the risk of complications including cirrhosis and liver failure. Tests like the viral load or liver function tests are used to evaluate if medicines are working. People who have large amounts of the virus in their blood are at highest risk to get cirrhosis. Up to one-third of people with very high viral loads (more than one million viral copies per milliliter of blood) will develop cirrhosis over a decade, compared to only 4.5% of those with low viral loads (less than 300 viral copies per milliliter). Continue reading